Primary plasma cell leukaemia (PPCL) is a rare form of plasma cell neoplasm. Treatments of PPCL have been most disappointing. A patient with PPCL received high‐dose melphalan plus total body irradiation and autologous bone marrow transplantation (ABMT). By using third‐complementarity‐determining region (CDRIII)‐specific probes, minimal residual disease (MRD) was detected in remission marrow, collected 1 month before ABMT. MRD was no longer detected by CDRIII‐specific probes 6, 19 and 26 months after transplantation. The patient remained in complete remission up to 59 months after ABMT.
|Original language||English (US)|
|Number of pages||3|
|Journal||British journal of haematology|
|State||Published - Apr 1995|
- primary plasma cell leukaemia
ASJC Scopus subject areas